BC 19Alternative Names: BC-19
Latest Information Update: 18 Aug 2010
At a glance
- Originator Biocortech
- Developer MarcoPolo Pharmaceuticals SA
- Class Alkaloids
- Mechanism of Action Adrenergic receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Major depressive disorder
Most Recent Events
- 31 Mar 2010 Clinical trials in Depression in France (unspecified route)